-
The positive relationship between the amount of surgical residual following primary extirpation of advanced ovarian cancer and survival thereafter has been one frequently cited to justify aggressive surgical evaluation.
-
-
Which Antipsychotics Are More Dangerous?; Should CPOE Undergo Evaluation?; New Treatment for Tennis Elbow; FDA Actions
-
It has become increasingly documented that removal of the ovaries in high-risk women can not only reduce the risk of gynecologic malignancy but also improve the outcome of women with breast cancer.
-
Rebbeck and colleagues identified a cohort of 462 women with BRCA1/2 mutations from 13 medical centers in North America and Europe.
-
-
Letrozole for Postmenopausal Women with Breast Cancer; Do Antidepressants Increase Risk of Suicide?; Can Viagra Improve Heart Function?; Can Tamoxifen Increase Your Height?; A Dramatic Increase of Clostridium difficile; FDA Actions
-
Prostate cancer is one of the leading causes of cancer in men, both in this country and in Europe. Recognizing that the primary care physician often is the first health care professional who determines whether a PSA test is ordered and often is crucial in directing further follow-up relating to diagnosis and treatment selection, Part II will deal with important information regarding the choices for treating prostate cancer, and the side effects, efficacy, and quality-of-life issues that result from treatment.
-
FDA Recommends Approval of Muraglitazar, But May Need To Reconsider; Which Antipsychotics Are More Dangerous?; Should CPOE Undergo Evaluation?; New Treatment for Tennis Elbow; FDA Actions
-
A new drug has been approved for the treatment of children with below average height who are resistant to growth hormone. Mecasermin is a human insulin-like growth factor-1 (IGF-1) that is produced by recombinant DNA technology. This protein is marketed by Tercica, Incorporated as Increlex.